share_log

Organovo Highlights Phase 2 Results For FXR314 In MASH At The Liver Meeting, Showing Significant Liver Fat Reduction And Improved Safety Profile Compared To Other FXR Agonists

Benzinga ·  Nov 20, 2024 21:08
Organovo Highlights Phase 2 Results For FXR314 In MASH At The Liver Meeting, Showing Significant Liver Fat Reduction And Improved Safety Profile Compared To Other FXR Agonists
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment